207 related articles for article (PubMed ID: 18223234)
1. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
Hu P; Arias RS; Sadun RE; Nien YC; Zhang N; Sabzevari H; Lutsiak ME; Khawli LA; Epstein AL
Clin Cancer Res; 2008 Jan; 14(2):579-88. PubMed ID: 18223234
[TBL] [Abstract][Full Text] [Related]
2. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
4. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
Zhang N; Sadun RE; Arias RS; Flanagan ML; Sachsman SM; Nien YC; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2007 May; 13(9):2758-67. PubMed ID: 17460060
[TBL] [Abstract][Full Text] [Related]
5. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.
Sadun RE; Hsu WE; Zhang N; Nien YC; Bergfeld SA; Sabzevari H; Lutsiak ME; Khawli L; Hu P; Epstein AL
J Immunother; 2008 Apr; 31(3):235-45. PubMed ID: 18317364
[TBL] [Abstract][Full Text] [Related]
6. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.
Nishikawa H; Kato T; Hirayama M; Orito Y; Sato E; Harada N; Gnjatic S; Old LJ; Shiku H
Cancer Res; 2008 Jul; 68(14):5948-54. PubMed ID: 18632650
[TBL] [Abstract][Full Text] [Related]
9. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells engineered to express GITRL enhance therapeutic immunity in murine Lewis lung carcinoma.
Ma J; Wang S; Ma B; Mao C; Tong J; Yang M; Wu C; Jiao Z; Lu L; Xu H
Cancer Lett; 2011 Feb; 301(2):142-50. PubMed ID: 21186078
[TBL] [Abstract][Full Text] [Related]
11. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
12. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
13. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
[TBL] [Abstract][Full Text] [Related]
14. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
15. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
16. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
[TBL] [Abstract][Full Text] [Related]
17. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
18. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
[TBL] [Abstract][Full Text] [Related]
19. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]